Intravenous irons: From basic science to clinical practice

Pharmaceuticals

Volumn 11, Issue 3, 2018, Pages

  Bhandari, Sunil ^a   Pereira, Dora I A ^b,c   Chappell, Helen F ^d   Drakesmith, Hal ^e,f  

^a HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

Adverse event profile; Anaemia; Bioengineering; Intravenous iron; Iron processing; Iron carbohydrate complex; Labile iron

Indexed keywords

HEPCIDIN; IRON; IRON REGULATORY FACTOR;

BIOENGINEERING; BIOEQUIVALENCE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; HUMAN; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; IRON METABOLISM; MINERAL SUPPLEMENTATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW;

EID: 85052508404     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph11030082     Document Type: Review

References (167)

1. Paul, B.T.; Manz, D.H.; Torti, F.M.; Torti, S.V. Mitochondria and iron: Current questions. Expert Rev. Hematol 2017, 10, 65–79. doi:10.1080/17474086.2016.1268047.
2. Anderson, C.P.; Shen, M.; Eisenstein, R.S.; Leibold, E.A. Mammalian iron metabolism and its control by iron regulatory proteins. Biochim. Biophys. Acta 2012, 1823, 1468–1483. doi:10.1016/j.bbamcr.2012.05.010.
3. Muckenthaler, M.U.; Rivella, S.; Hentze, M.W.; Galy, B. A red carpet for iron metabolism. Cell 2017, 168, 344–361. doi:10.1016/j.cell.2016.12.034.
4. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990– 2016: A systematic analysis for the global burden of disease study 2016. Lancet 2017, 390, 1211–1259. doi:10.1016/S0140-6736(17)32154-2.
5. Tolkien, Z.; Stecher, L.; Mander, A.P.; Pereira, D.I.; Powell, J.J. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: A systematic review and meta-analysis. PLoS ONE 2015, doi:10.1371/journal.pone.0117383.
6. Cappellini, M.D.; Comin-Colet, J.; de Francisco, A.; Dignass, A.; Doehner, W.; Lam, C.S.; Macdougall, I.C.; Rogler, G.; Camaschella, C.; Kadir, R. et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am. J. Hematol. 2017, 92, 1068 doi:10.1002/ajh.24820.
7. Camaschella, C. Iron deficiency: New insights into diagnosis and treatment. Hematol. Am. Soc. Hematol. Educ. Program. 2015, 2015, 8–13. doi:10.1182/asheducation-2015.1.8.
8. Butcher, A.; Richards, T. Cornerstones of patient blood management in surgery. Transfus. Med. 2017, 28, 150–157. doi:10.1111/tme.12476.
9. Litton, E.; Xiao, J.; Ho, K.M. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: Systematic review and meta-analysis of randomised clinical trials. BMJ 2013, doi:10.1136/bmj.f4822.
10. Moretti, D.; Goede, J.S.; Zeder, C.; Jiskra, M.; Chatzinakou, V.; Tjalsma, H.; Melse-Boonstra, A.; Brittenham, G.; Swinkels, D.W.; Zimmermann, M.B. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood 2015, 126, 1981–1989. doi:10.1182/blood-2015-05-642223.
11. Stoffel, N.U.; Cercamondi, C.I.; Brittenham, G.; Zeder, C.; Geurts-Moespot, A.J.; Swinkels, D.W.; Moretti, D.; Zimmermann, M.B. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: Two open-label, randomised controlled trials. Lancet Haematol. 2017, 4, e524–e533. doi:10.1016/S2352-3026(17)30182-5.
12. Finberg, K.E.; Heeney, M.M.; Campagna, D.R.; Aydinok, Y.; Pearson, H.A.; Hartman, K.R.; Mayo, M.M.; Samuel, S.M.; Strouse, J.J.; Markianos, K. et al. Mutations in tmprss6 cause iron-refractory iron deficiency anemia (irida). Nat. Genet. 2008, 40, 569–571. doi:10.1038/ng.130.
13. Girelli, D.; Ugolini, S.; Busti, F.; Marchi, G.; Castagna, A. Modern iron replacement therapy: Clinical and pathophysiological insights. Int. J. Hematol. 2018, 107, 16–30. doi:10.1007/s12185-017-2373-3.
14. Fishbane, S.; Block, G.A.; Loram, L.; Neylan, J.; Pergola, P.E.; Uhlig, K.; Chertow, G.M. Effects of ferric citrate in patients with nondialysis-dependent ckd and iron deficiency anemia. J. Am. Soc. Nephrol. 2017, 28, 1851–1858. doi:10.1681/ASN.2016101053.
15. Camaschella, C. Iron and hepcidin: A story of recycling and balance. Hematol. Am. Soc. Hematol. Educ. Program. 2013, 2013, 1–8. doi:10.1182/asheducation-2013.1.1.
16. Schmidt, P.J. Regulation of iron metabolism by hepcidin under conditions of inflammation. J. Biol. Chem. 2015, 290, 18975–18983. doi:10.1074/jbc.R115.650150.
17. Fishbane, S.; Spinowitz, B. Update on anemia in esrd and earlier stages of ckd: Core curriculum 2018. Am. J. Kidney Dis. 2018, 71, 423–435. doi:10.1053/j.ajkd.2017.09.026.
18. Fishbane, S. Balance of benefit and risk in intravenous iron treatment in chronic kidney disease. Semin. Nephrol. 2016, 36, 119–123. doi:10.1016/j.semnephrol.2016.02.006.
19. Weiss, G.; Goodnough, L.T. Anemia of chronic disease. N. Engl. J. Med. 2005, 352, 1011–1023. doi:10.1056/NEJMra041809.
20. Auerbach, M.; Munoz, M.; Macdougall, I.C. Intravenous iron: Out of sight, out of mind. Lancet Haematol. 2018, 5, e10–e12. doi:10.1016/S2352-3026(17)30230-2.
21. Hilty, F.M.; Arnold, M.; Hilbe, M.; Teleki, A.; Knijnenburg, J.T.; Ehrensperger, F.; Hurrell, R.F.; Pratsinis, S.E.; Langhans, W.; Zimmermann, M.B. Iron from nanocompounds containing iron and zinc is highly bioavailable in rats without tissue accumulation. Nat. Nanotechnol. 2010, 5, 374–380. doi:10.1038/nnano.2010.79.
22. Powell, J.J.; Bruggraber, S.F.; Faria, N.; Poots, L.K.; Hondow, N.; Pennycook, T.J.; Latunde-Dada, G.O.; Simpson, R.J.; Brown, A.P.; Pereira, D.I. A nano-disperse ferritin-core mimetic that efficiently corrects anemia without luminal iron redox activity. Nanomedicine 2014, 10, 1529–1538. doi:10.1016/j.nano.2013.12.011.
23. Pisani, A.; Riccio, E.; Sabbatini, M.; Andreucci, M.; Del Rio, A.; Visciano, B. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in ckd patients: A. randomized trial. Nephrol. Dial. Transplant. 2015, 30, 645–652. doi:10.1093/ndt/gfu357.
24. Shafie, E.H.; Keshavarz, S.A.; Kefayati, M.E.; Taheri, F.; Sarbakhsh, P.; Vafa, M.R. The effects of nanoparticles containing iron on blood and inflammatory markers in comparison to ferrous sulfate in anemic rats. Int. J. Prev. Med. 2016, 7. doi:10.4103/2008-7802.193092.
25. Garces, V.; Rodriguez-Nogales, A.; Gonzalez, A.; Galvez, N.; Rodriguez-Cabezas, M.E.; Garcia-Martin, M.L.; Gutierrez, L.; Rondon, D.; Olivares, M.; Galvez, J. et al. Bacteria-carried iron oxide nanoparticles for treatment of anemia. Bioconjug. Chem. 2018, 29, 1785–1791. doi:10.1021/acs.bioconjchem.8b00245.
26. Ganz, T. Systemic iron homeostasis. Physiol. Rev. 2013, 93, 1721–1741. doi:10.1152/physrev.00008.2013.
27. Pereira, D.I.; Bruggraber, S.F.; Faria, N.; Poots, L.K.; Tagmount, M.A.; Aslam, M.F.; Frazer, D.M.; Vulpe, C.D.; Anderson, G.J.; Powell, J.J. Nanoparticulate iron(iii) oxo-hydroxide delivers safe iron that is well absorbed and utilised in humans. Nanomedicine 2014, 10, 1877–1886. doi:10.1016/j.nano.2014.06.012.
28. Gasche, C.; Ahmad, T.; Tulassay, Z.; Baumgart, D.C.; Bokemeyer, B.; Buning, C.; Howaldt, S.; Stallmach, A.; Group, A.S. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: Results from a phase-3 clinical trial program. Inflamm. Bowel Dis. 2015, 21, 579–588. doi:10.1097/MIB.0000000000000314.
29. Barraclough, K.A.; Brown, F.; Hawley, C.M.; Leary, D.; Noble, E.; Campbell, S.B.; Isbel, N.M.; Mudge, D.W.; van Eps, C.L.; Johnson, D.W. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: Hematocrit trial. Nephrol. Dial. Transplant. 2012, 27, 4146–4153. doi:10.1093/ndt/gfs372.
30. Nagaraju, S.P.; Cohn, A.; Akbari, A.; Davis, J.L.; Zimmerman, D.L. Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: A randomized controlled trial. BMC Nephrol. 2013, 14. doi:10.1186/1471-2369-14-64.
31. Auerbach, M.; Macdougall, I. The available intravenous iron formulations: History, efficacy, and toxicology. Hemodial. Int. 2017, 21 (Suppl. 1), S83–S92. doi:10.1111/hdi.12560.
32. Jahn, M.R.; Andreasen, H.B.; Futterer, S.; Nawroth, T.; Schunemann, V.; Kolb, U.; Hofmeister, W.; Munoz, M.; Bock, K.; Meldal, M. et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (monofer), a new intravenous iron preparation and its clinical implications. Eur. J. Pharm. Biopharm. 2011, 78, 480–491. doi:10.1016/j.ejpb.2011.03.016.
33. Grzywacz, A.; Lubas, A.; Fiedor, P.; Fiedor, M.; Niemczyk, S. Safety and efficacy of intravenous administration of iron preparations. Acta Pol. Pharm. 2017, 74, 13–24.
34. Neiser, S.; Koskenkorva, T.S.; Schwarz, K.; Wilhelm, M.; Burckhardt, S. Assessment of dextran antigenicity of intravenous iron preparations with enzyme-linked immunosorbent assay (elisa). Int. J. Mol. Sci. 2016, 17. doi:10.3390/ijms17071185.
35. Koskenkorva-Frank, T.S.; Weiss, G.; Koppenol, W.H.; Burckhardt, S. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: Insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic. Biol. Med. 2013, 65, 1174–1194. doi:10.1016/j.freeradbiomed.2013.09.001.
36. Toblli, J.E.; Angerosa, M. Optimizing iron delivery in the management of anemia: Patient considerations and the role of ferric carboxymaltose. Drug Des. Devel. Ther. 2014, 8, 2475–2491. doi:10.2147/DDDT.S55499.
37. Neiser, S.; Rentsch, D.; Dippon, U.; Kappler, A.; Weidler, P.G.; Gottlicher, J.; Steininger, R.; Wilhelm, M.; Braitsch, M.; Funk, F. et al. Physico-chemical properties of the new generation iv iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose. Biometals 2015, 28, 615–635. doi:10.1007/s10534-015-9845-9.
38. Pai, A.B. Complexity of intravenous iron nanoparticle formulations: Implications for bioequivalence evaluation. Ann. N. Y. Acad. Sci. 2017, 1407, 17–25. doi:10.1111/nyas.13461.
39. Geisser, P.; Burckhardt, S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011, 3, 12–33. doi:10.3390/pharmaceutics3010012.
40. Chappell, H.F.; Thom, W.; Bowron, D.T.; Faria, N.; Hasnip, P.J.; Powell, J.J. Structure of naturally hydrated ferrihydrite revealed through neutron diffraction and first-principles modeling. Phys. Rev. Mater. 2017, 1. doi:10.1103/PhysRevMaterials.1.036002.
41. Gustafson, H.H.; Holt-Casper, D.; Grainger, D.W.; Ghandehari, H. Nanoparticle uptake: The phagocyte problem. Nano Today 2015, 10, 487–510. doi:10.1016/j.nantod.2015.06.006.
42. Skotland, T.; Sontum, P.C.; Oulie, I. In vitro stability analyses as a model for metabolism of ferromagnetic particles (clariscan), a contrast agent for magnetic resonance imaging. J. Pharm. Biomed. Anal. 2002, 28, 323–329.
43. Maneeprakorn, W.; Maurizi, L.; Siriket, H.; Wutikhun, T.; Dharakul, T.; Hofmann, H. Superparamagnetic nanohybrids with cross-linked polymers providing higher in vitro stability. J. Mater. Sci. 2017, 52, 9249–9261 doi:10.1007/s10853-017-1098-2.
44. Corna, G.; Campana, L.; Pignatti, E.; Castiglioni, A.; Tagliafico, E.; Bosurgi, L.; Campanella, A.; Brunelli, S.; Manfredi, A.A.; Apostoli, P. et al. Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica 2010, 95, 1814–1822. doi:10.3324/haematol.2010.023879.
45. Nairz, M.; Theurl, I.; Swirski, F.K.; Weiss, G. “Pumping iron”-how macrophages handle iron at the systemic, microenvironmental, and cellular levels. Pflugers Arch. 2017, 469, 397–418. doi:10.1007/s00424-017-1944-8.
46. Agoro, R.; Taleb, M.; Quesniaux, V.F.J.; Mura, C. Cell iron status influences macrophage polarization. PLoS ONE 2018, 13. doi:10.1371/journal.pone.0196921.
47. Drakesmith, H.; Nemeth, E.; Ganz, T. Ironing out ferroportin. Cell Metab. 2015, 22, 777–787. doi:10.1016/j.cmet.2015.09.006.
48. Macdougall, I.C.; Vernon, K. Complement activation-related pseudo-allergy: A fresh look at hypersensitivity reactions to intravenous iron. Am. J. Nephrol. 2017, 45, 60–62. doi:10.1159/000451069.
49. Munoz, M.; Gomez-Ramirez, S.; Bhandari, S. The safety of available treatment options for iron-deficiency anemia. Expert Opin. Drug Saf. 2018, 17, 149–159. doi:10.1080/14740338.2018.1400009.
50. Slotki, I.; Cabantchik, Z.I. The labile side of iron supplementation in ckd. J. Am. Soc. Nephrol. 2015, 26, 2612–2630 doi:10.1681/ASN.2015010052.
51. Cooke, M.; Lamplugh, A.; Naudeer, S.; Edey, M.; Bhandari, S. Efficacy and tolerability of accelerated-dose low-molecular-weight iron dextran (cosmofer) in patients with chronic kidney disease. Am. J. Nephrol. 2012, 35, 69–74. doi:10.1159/000334877.
52. Sinha, S.; Chiu, D.; Peebles, G.; Swoboda, P.; Kolakkat, S.; Lamerton, E.; Fenwick, S.; Bhandari, S.; Kalra, P.A. Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients. QJM 2011, 104, 221–230. doi:10.1093/qjmed/hcq180.
53. Chertow, G.M.; Mason, P.D.; Vaage-Nilsen, O.; Ahlmen, J. Update on adverse drug events associated with parenteral iron. Nephrol. Dial. Transplant. 2006, 21, 378–382. doi:10.1093/ndt/gfi253.
54. Auerbach, M.; Pappadakis, J.A.; Bahrain, H.; Auerbach, S.A.; Ballard, H.; Dahl, N.V. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (infed) for the treatment of iron deficient anemia. Am. J. Hematol. 2011, 86, 860–862. doi:10.1002/ajh.22153.
55. Rampton, D.; Folkersen, J.; Fishbane, S.; Hedenus, M.; Howaldt, S.; Locatelli, F.; Patni, S.; Szebeni, J.; Weiss, G. Hypersensitivity reactions to intravenous iron: Guidance for risk minimization and management. Haematologica 2014, 99, 1671–1676. doi:10.3324/haematol.2014.111492.
56. Di Francesco, T.; Philipp, E.; Borchard, G. Iron sucrose: Assessing the similarity between the originator drug and its intended copies. Ann. N. Y. Acad. Sci. 2017, 1407, 63–74. doi:10.1111/nyas.13517.
57. Toblli, J.E.; Cao, G.; Giani, J.F.; Dominici, F.P.; Angerosa, M. Nitrosative stress and apoptosis by intravenous ferumoxytol, iron isomaltoside 1000, iron dextran, iron sucrose, and ferric carboxymaltose in a nonclinical model. Drug Res. 2015, 65, 354–360. doi:10.1055/s-0034-1384534.
58. Rottembourg, J.; Guerin, A.; Diaconita, M.; Kadri, A. The complete study of the switch from iron-sucrose originator to iron-sucrose similar and vice versa in hemodialysis patients. J. Kidney 2016, 2. doi:10.4172/2472-1220.1000110.
59. Rottembourg, J.; Kadri, A.; Leonard, E.; Dansaert, A.; Lafuma, A. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol. Dial. Transplant. 2011, 26, 3262–3267. doi:10.1093/ndt/gfr024.
60. Aguera, M.L.; Martin-Malo, A.; Alvarez-Lara, M.A.; Garcia-Montemayor, V.E.; Canton, P.; Soriano, S.; Aljama, P. Efficiency of original versus generic intravenous iron formulations in patients on haemodialysis. PLoS ONE 2015, 10. doi:10.1371/journal.pone.0135967.
61. Stein, J.; Dignass, A.; Chow, K.U. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr. Med. Res. Opin. 2012, 28, 241–243. doi:10.1185/03007995.2011.651527.
62. Martin-Malo, A.; Merino, A.; Carracedo, J.; Alvarez-Lara, M.A.; Ojeda, R.; Soriano, S.; Crespo, R.; Ramirez, R.; Aljama, P. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol. Dial. Transplant. 2012, 27, 2465–2471. doi:10.1093/ndt/gfr711.
63. Lee, E.S.; Park, B.R.; Kim, J.S.; Choi, G.Y.; Lee, J.J.; Lee, I.S. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr. Med. Res. Opin. 2013, 29, 141–147. doi:10.1185/03007995.2012.760444.
64. FDA. Draft Guidance on Iron Sucrose. Available online: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM29 7630.pdf (accessed on 15 March 2018).
65. FDA. Draft Guidance on Sodium Ferric Gluconate Complex. Available online: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm35814 2.pdf (accessed on 15 March 2018).
66. EMA. Reflection Paper on the Data Requirements for Intravenous Iron-Based Nano-Colloidal Products Developed with Reference to an Innovator Medicinal Product. Ema/chmp/swp/620008/2012. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500184922 (accessed on 23 February 2018).
67. Avni, T.; Bieber, A.; Grossman, A.; Green, H.; Leibovici, L.; Gafter-Gvili, A. The safety of intravenous iron preparations: Systematic review and meta-analysis. Mayo Clin. Proc. 2015, 90, 12–23. doi:10.1016/j.mayocp.2014.10.007.
68. EU Clinical Trials Register. UK Multicentre Open-Label Randomised Controlled Trial of Iv Iron Therapy in Incident Haemodialysis Patients. 2013-002267-25. Available online: https://www.clinicaltrialsregister.eu/ctr-search/search (accessed on 07 June 2018).
69. Macdougall, I.C.; Bock, A.H.; Carrera, F.; Eckardt, K.U.; Gaillard, C.; Van Wyck, D.; Meier, Y.; Larroque, S.; Roger, S.D.; investigators, F.C.S. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: An analysis of the randomized find-ckd trial. BMC Nephrol. 2017, 18. doi:10.1186/s12882-017-0444-6.
70. Gaillard, C.A.; Bock, A.H.; Carrera, F.; Eckardt, K.U.; Van Wyck, D.B.; Bansal, S.S.; Cronin, M.; Meier, Y.; Larroque, S.; Roger, S.D. et al. Hepcidin response to iron therapy in patients with non-dialysis dependent ckd: An analysis of the find-ckd trial. PLoS ONE 2016, 11. doi:10.1371/journal.pone.0157063.
71. Kalra, P.A.; Bhandari, S.; Saxena, S.; Agarwal, D.; Wirtz, G.; Kletzmayr, J.; Thomsen, L.L.; Coyne, D.W. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol. Dial. Transplant. 2016, 31, 646–655. doi:10.1093/ndt/gfv293.
72. Syed, A.; Bhandari, S. Correction of iron deficiency anaemia using iv cosmofer in ckd patients with asthma: A prospective study. QJM 2016, 109, 187–190. doi:10.1093/qjmed/hcv117.
73. Toblli, J.E.; Di Gennaro, F. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: Effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. PLoS ONE 2015, 10. doi:10.1371/journal.pone.0125528.
74. Macdougall, I.C.; Bock, A.H.; Carrera, F.; Eckardt, K.U.; Gaillard, C.; Van Wyck, D.; Roubert, B.; Nolen, J.G.; Roger, S.D.; Investigators, F.-C.S. Find-ckd: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol. Dial. Transplant. 2014, 29, 2075–2084. doi:10.1093/ndt/gfu201.
75. Bhandari, S.; Kalra, P.A.; Kothari, J.; Ambuhl, P.M.; Christensen, J.H.; Essaian, A.M.; Thomsen, L.L.; Macdougall, I.C.; Coyne, D.W. A randomized, open-label trial of iron isomaltoside 1000 (monofer(r)) compared with iron sucrose (venofer(r)) as maintenance therapy in haemodialysis patients. Nephrol. Dial. Transplant. 2015, 30, 1577–1589. doi:10.1093/ndt/gfv096.
76. Kuji, T.; Toya, Y.; Fujikawa, T.; Kakimoto-Shino, M.; Nishihara, M.; Shibata, K.; Tamura, K.; Hirawa, N.; Satta, H.; Kawata, S. et al. Acceleration of iron utilization after intravenous iron administration during activated erythropoiesis in hemodialysis patients: A randomized study. Ther. Apher. Dial. 2015, 19, 131–140 doi:10.1111/1744-9987.12237.
77. Macdougall, I.C.; Strauss, W.E.; McLaughlin, J.; Li, Z.; Dellanna, F.; Hertel, J. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with ckd. Clin. J. Am. Soc. Nephrol. 2014, 9, 705–712. doi:10.2215/CJN.05320513.
78. Onken, J.E.; Bregman, D.B.; Harrington, R.A.; Morris, D.; Buerkert, J.; Hamerski, D.; Iftikhar, H.; Mangoo-Karim, R.; Martin, E.R.; Martinez, C.O. et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: The repair-ida trial. Nephrol. Dial. Transplant. 2014, 29, 833–842. doi:10.1093/ndt/gft251.
79. Arogundade, F.A.; Soyinka, F.O.; Sanusi, A.A.; Ojo, O.E.; Akinsola, A. Iron status and benefit of the use of parenteral iron therapy in pre-dialysis chronic kidney disease patients. Niger. Postgrad. Med. J. 2013, 20, 299–304.
80. Charytan, C.; Bernardo, M.V.; Koch, T.A.; Butcher, A.; Morris, D.; Bregman, D.B. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: A randomized, active-controlled, multi-center study. Nephrol. Dial. Transplant. 2013, 28, 953–964. doi:10.1093/ndt/gfs528.
81. Wikstrom, B.; Bhandari, S.; Barany, P.; Kalra, P.A.; Ladefoged, S.; Wilske, J.; Thomsen, L.L. Iron isomaltoside 1000: A new intravenous iron for treating iron deficiency in chronic kidney disease. J. Nephrol. 2011, 24, 589–596. doi:10.5301/JN.2011.6248.
82. Adhikary, L.; Acharya, S. Efficacy of iv iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy. J. Nepal. Med. Assoc. 2011, 51, 133–136.
83. Qunibi, W.Y.; Martinez, C.; Smith, M.; Benjamin, J.; Mangione, A.; Roger, S.D. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol. Dial. Transplant. 2011, 26, 1599–1607. doi:10.1093/ndt/gfq613.
84. Covic, A.; Mircescu, G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: A multi-centre, open-label, clinical study. Nephrol. Dial. Transplant. 2010, 25, 2722–2730. doi:10.1093/ndt/gfq069.
85. Bailie, G.R.; Mason, N.A.; Valaoras, T.G. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Hemodial. Int. 2010, 14, 47–54. doi:10.1111/j.1542-4758.2009.00409.x.
86. Spinowitz, B.S.; Kausz, A.T.; Baptista, J.; Noble, S.D.; Sothinathan, R.; Bernardo, M.V.; Brenner, L.; Pereira, B.J. Ferumoxytol for treating iron deficiency anemia in ckd. J. Am. Soc. Nephrol. 2008, 19, 1599–1605. doi:10.1681/ASN.2007101156.
87. Agarwal, R.; Rizkala, A.R.; Bastani, B.; Kaskas, M.O.; Leehey, D.J.; Besarab, A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am. J. Nephrol. 2006, 26, 445–454. doi:10.1159/000096174.
88. Mircescu, G.; Garneata, L.; Capusa, C.; Ursea, N. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol. Dial. Transplant. 2006, 21, 120–124. doi:10.1093/ndt/gfi087.
89. Van Wyck, D.B.; Roppolo, M.; Martinez, C.O.; Mazey, R.M.; McMurray, S.; United States Iron Sucrose Clinical Trials, G. A randomized, controlled trial comparing iv iron sucrose to oral iron in anemic patients with nondialysis-dependent ckd. Kidney Int. 2005, 68, 2846–2856. doi:10.1111/j.1523-1755.2005.00758.x.
90. Charytan, C.; Qunibi, W.; Bailie, G.R.; Venofer Clinical Studies, G. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin. Pract. 2005, 100, C55–C62. doi:10.1159/000085049.
91. Goldstein, S.L.; Morris, D.; Warady, B.A. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with ckd: A randomized controlled trial. Am. J. Kidney Dis. 2013, 61, 588–597. doi:10.1053/j.ajkd.2012.10.019.
92. Li, X.; Kshirsagar, A.V.; Brookhart, M.A. Safety of intravenous iron in hemodialysis patients. Hemodial. Int. 2017, 21 (Suppl. 1), S93–S103. doi:10.1111/hdi.12558.
93. Aronoff, G.R.; Bennett, W.M.; Blumenthal, S.; Charytan, C.; Pennell, J.P.; Reed, J.; Rothstein, M.; Strom, J.; Wolfe, A.; Van Wyck, D. et al. Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens. Kidney Int. 2004, 66, 1193–1198. doi:10.1111/j.1523-1755.2004.00872.x.
94. Chandler, G.; Harchowal, J.; Macdougall, I.C. Intravenous iron sucrose: Establishing a safe dose. Am. J. Kidney Dis. 2001, 38, 988–991. doi:10.1053/ajkd.2001.28587.
95. Charytan, C.; Levin, N.; Al-Saloum, M.; Hafeez, T.; Gagnon, S.; VanWyck, D.B. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am. J. Kidney Dis. 2001, 37, 300–307. doi:10.1053/ajkd.2001.21293.
96. Van Wyck, D.B.; Cavallo, G.; Spinowitz, B.S.; Adhikarla, R.; Gagnon, S.; Charytan, C.; Levin, N. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am. J. Kidney Dis. 2000, 36, 88–97. doi:10.1053/ajkd.2000.8276.
97. Roger, S.D.; Gaillard, C.A.; Bock, A.H.; Carrera, F.; Eckardt, K.U.; Van Wyck, D.B.; Cronin, M.; Meier, Y.; Larroque, S.; Macdougall, I.C. et al. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent ckd: An analysis of the 1-year find-ckd trial. Nephrol. Dial. Transplant. 2017, 32, 1530–1539. doi:10.1093/ndt/gfw264.
98. Macdougall, I.C.; Bock, A.H.; Carrera, F.; Eckardt, K.U.; Gaillard, C.; Wyck, D.V.; Meier, Y.; Larroque, S.; Perrin, A.; Roger, S.D. Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the find-ckd trial. Clin. Nephrol. 2017, 88, 301–310. doi:10.5414/CN109198.
99. Zeidan, A.; Bhandari, S. Anemia in peritoneal dialysis patients; iron repletion, current and future therapies. Perit. Dial. Int. 2017, 37, 6–13. doi:10.3747/pdi.2016.00193.
100. Van Veldhuisen, D.J.; Ponikowski, P.; van der Meer, P.; Metra, M.; Bohm, M.; Doletsky, A.; Voors, A.A.; Macdougall, I.C.; Anker, S.D.; Roubert, B. et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 2017, 136, 1374–1383. doi:10.1161/CIRCULATIONAHA.117.027497.
101. Toblli, J.E.; Di Gennaro, F.; Rivas, C. Changes in echocardiographic parameters in iron deficiency patients with heart failure and chronic kidney disease treated with intravenous iron. Heart Lung Circ. 2015, 24, 686–690 doi:10.1016/j.hlc.2014.12.161.
102. Ponikowski, P.; van Veldhuisen, D.J.; Comin-Colet, J.; Ertl, G.; Komajda, M.; Mareev, V.; McDonagh, T.; Parkhomenko, A.; Tavazzi, L.; Levesque, V. et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur. Heart J. 2015, 36, 657–668. doi:10.1093/eurheartj/ehu385.
103. Filippatos, G.; Farmakis, D.; Colet, J.C.; Dickstein, K.; Luscher, T.F.; Willenheimer, R.; Parissis, J.; Gaudesius, G.; Mori, C.; von Eisenhart Rothe, B. et al. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: A subanalysis of the fair-hf trial. Eur. J. Heart Fail. 2013, 15, 1267–1276. doi:10.1093/eurjhf/hft099.
104. Beck-da-Silva, L.; Piardi, D.; Soder, S.; Rohde, L.E.; Pereira-Barretto, A.C.; de Albuquerque, D.; Bocchi, E.; Vilas-Boas, F.; Moura, L.Z.; Montera, M.W. et al. Iron-hf study: A randomized trial to assess the effects of iron in heart failure patients with anemia. Int. J. Cardiol. 2013, 168, 3439–3442. doi:10.1016/j.ijcard.2013.04.181.
105. Van Craenenbroeck, E.M.; Conraads, V.M.; Greenlaw, N.; Gaudesius, G.; Mori, C.; Ponikowski, P.; Anker, S.D. The effect of intravenous ferric carboxymaltose on red cell distribution width: A subanalysis of the fair-hf study. Eur. J. Heart Fail. 2013, 15, 756–762. doi:10.1093/eurjhf/hft068.
106. Comin-Colet, J.; Lainscak, M.; Dickstein, K.; Filippatos, G.S.; Johnson, P.; Luscher, T.F.; Mori, C.; Willenheimer, R.; Ponikowski, P.; Anker, S.D. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: A subanalysis of the fair-hf study. Eur. Heart J. 2013, 34, 30–38. doi:10.1093/eurheartj/ehr504.
107. Anker, S.D.; Comin Colet, J.; Filippatos, G.; Willenheimer, R.; Dickstein, K.; Drexler, H.; Luscher, T.F.; Bart, B.; Banasiak, W.; Niegowska, J. et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 2009, 361, 2436–2448. doi:10.1056/NEJMoa0908355.
108. Okonko, D.O.; Grzeslo, A.; Witkowski, T.; Mandal, A.K.; Slater, R.M.; Roughton, M.; Foldes, G.; Thum, T.; Majda, J.; Banasiak, W. et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency ferric-hf: A randomized, controlled, observer-blinded trial. J. Am. Coll. Cardiol. 2008, 51, 103–112. doi:10.1016/j.jacc.2007.09.036.
109. Bolger, A.P.; Bartlett, F.R.; Penston, H.S.; O’Leary, J.; Pollock, N.; Kaprielian, R.; Chapman, C.M. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J. Am. Coll. Cardiol. 2006, 48, 1225–1227. doi:10.1016/j.jacc.2006.07.015.
110. Minana, G.; Cardells, I.; Palau, P.; Llacer, P.; Facila, L.; Almenar, L.; Lopez-Lereu, M.P.; Monmeneu, J.V.; Amiguet, M.; Gonzalez, J. et al. Changes in myocardial iron content following administration of intravenous iron (myocardial-iron): Study design. Clin. Cardiol. 2018, 41, 729–735. doi:10.1002/clc.22956.
111. Dahlerup, J.F.; Jacobsen, B.A.; van der Woude, J.; Bark, L.A.; Thomsen, L.L.; Lindgren, S. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand. J. Gastroenterol. 2016, 51, 1332–1338. doi:10.1080/00365521.2016.1196496.
112. Reinisch, W.; Altorjay, I.; Zsigmond, F.; Primas, C.; Vogelsang, H.; Novacek, G.; Reinisch, S.; Thomsen, L.L. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand. J. Gastroenterol. 2015, 50, 1226–1233. doi:10.3109/00365521.2015.1031168.
113. Reinisch, W.; Staun, M.; Tandon, R.K.; Altorjay, I.; Thillainayagam, A.V.; Gratzer, C.; Nijhawan, S.; Thomsen, L.L. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (monofer) compared with oral iron for treatment of anemia in ibd (proceed). Am. J. Gastroenterol. 2013, 108, 1877–1888. doi:10.1038/ajg.2013.335.
114. Nordfjeld, K.; Andreasen, H.; Thomsen, L.L. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease. Drug Des. Devel. Ther. 2012, 6, 43–51. doi:10.2147/DDDT.S30015.
115. Evstatiev, R.; Marteau, P.; Iqbal, T.; Khalif, I.L.; Stein, J.; Bokemeyer, B.; Chopey, I.V.; Gutzwiller, F.S.; Riopel, L.; Gasche, C. et al. Fergicor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011, 141, 846–853 e841–e842. doi:10.1053/j.gastro.2011.06.005.
116. Koutroubakis, I.E.; Oustamanolakis, P.; Karakoidas, C.; Mantzaris, G.J.; Kouroumalis, E.A. Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. Digest. Dis. Sci. 2010, 55, 2327–2331. doi:10.1007/s10620-009-1022-y.
117. Lindgren, S.; Wikman, O.; Befrits, R.; Blom, H.; Eriksson, A.; Granno, C.; Ung, K.A.; Hjortswang, H.; Lindgren, A.; Unge, P. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in ibd patients: A randomized, controlled, evaluator-blind, multicentre study. Scand. J. Gastroenterol. 2009, 44, 838–845. doi:10.1080/00365520902839667.
118. Kulnigg, S.; Stoinov, S.; Simanenkov, V.; Dudar, L.V.; Karnafel, W.; Garcia, L.C.; Sambuelli, A.M.; D’Haens, G.; Gasche, C. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (ferinject) randomized controlled trial. Am. J. Gastroenterol. 2008, 103, 1182–1192. doi:10.1111/j.1572-0241.2007.01744.x.
119. Schroder, O.; Mickisch, O.; Seidler, U.; de Weerth, A.; Dignass, A.U.; Herfarth, H.; Reinshagen, M.; Schreiber, S.; Junge, U.; Schrott, M. et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease—A randomized, controlled, open-label, multicenter study. Am. J. Gastroenterol. 2005, 100, 2503–2509. doi:10.1111/j.1572-0241.2005.00250.x.
120. Erichsen, K.; Ulvik, R.J.; Nysaeter, G.; Johansen, J.; Ostborg, J.; Berstad, A.; Berge, R.K.; Hausken, T. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand. J. Gastroenterol. 2005, 40, 1058–1065. doi:10.1080/00365520510023198.
121. Mahey, R.; Kriplani, A.; Mogili, K.D.; Bhatla, N.; Kachhawa, G.; Saxena, R. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. Int. J. Gynaecol. Obstet. 2016, 133, 43–48. doi:10.1016/j.ijgo.2015.09.007.
122. Tariq, N.; Ayub, R.; Khan, W.U.; Ijaz, S.; Alam, A.Y. Parenteral iron therapy in the treatment of iron deficiency anemia during pregnancy: A randomized controlled trial. J. Coll. Physicians Surg. Pak. 2015, 25, 193–197.
123. Kochhar, P.K.; Kaundal, A.; Ghosh, P. Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: A randomized clinical trial. J. Obstet. Gynaecol. Res. 2013, 39, 504–510. doi:10.1111/j.1447-0756.2012.01982.x.
124. Ayub, R.; Tariq, N.; Adil, M.M.; Iqbal, M.; Junaid, A.; Jaferry, T. Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J. Coll. Physicians Surg. Pak. 2008, 18, 424–427.
125. Al, R.A.; Unlubilgin, E.; Kandemir, O.; Yalvac, S.; Cakir, L.; Haberal, A. Intravenous versus oral iron for treatment of anemia in pregnancy: A randomized trial. Obstet. Gynecol. 2005, 106, 1335–1340. doi:10.1097/01.AOG.0000185260.82466.b4.
126. Bencaiova, G.; von Mandach, U.; Zimmermann, R. Iron prophylaxis in pregnancy: Intravenous route versus oral route. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009, 144, 135–139. doi:10.1016/j.ejogrb.2009.03.006.
127. Keeler, B.D.; Simpson, J.A.; Ng, O.; Padmanabhan, H.; Brookes, M.J.; Acheson, A.G. Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer. Br. J. Surg. 2017, 104, 214–221. doi:10.1002/bjs.10328.
128. Birgegard, G.; Henry, D.; Glaspy, J.; Chopra, R.; Thomsen, L.L.; Auerbach, M. A randomized noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: The profound trial. Pharmacotherapy 2016, 36, 402–414. doi:10.1002/phar.1729.
129. Borstlap, W.A.A.; Buskens, C.J.; Tytgat, K.; Tuynman, J.B.; Consten, E.C.J.; Tolboom, R.C.; Heuff, G.; van Geloven, N.; van Wagensveld, B.A.; Wientjes, C.A.C.A. et al. Multicentre randomized controlled trial comparing ferric(iii)carboxymaltose infusion with oral iron supplementation in the treatment of preoperative anaemia in colorectal cancer patients. BMC Surg. 2015, 15. doi:10.1186/s12893-015-0065-6.
130. Hedenus, M.; Karlsson, T.; Ludwig, H.; Rzychon, B.; Felder, M.; Roubert, B.; Birgegard, G. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med. Oncol. 2014, 31. doi:10.1007/s12032-014-0302-3.
131. Dangsuwan, P.; Manchana, T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol. Oncol. 2010, 116, 522–525. doi:10.1016/j.ygyno.2009.12.004.
132. Froessler, B.; Cocchiaro, C.; Saadat-Gilani, K.; Hodyl, N.; Dekker, G. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: A randomized trial. J. Matern Fetal Neonatal Med. 2013, 26, 654–659. doi:10.3109/14767058.2012.746299.
133. Michels, W.M.; Jaar, B.G.; Ephraim, P.L.; Liu, Y.; Miskulin, D.C.; Tangri, N.; Crews, D.C.; Scialla, J.J.; Shafi, T.; Sozio, S.M. et al. Intravenous iron administration strategies and anemia management in hemodialysis patients. Nephrol. Dial. Transplant. 2017, 32, 173–181. doi:10.1093/ndt/gfw316.
134. Brookhart, M.A.; Freburger, J.K.; Ellis, A.R.; Winkelmayer, W.C.; Wang, L.; Kshirsagar, A.V. Comparative short-term safety of sodium ferric gluconate versus iron sucrose in hemodialysis patients. Am. J. Kidney Dis. 2016, 67, 119–127. doi:10.1053/j.ajkd.2015.07.026.
135. Airy, M.; Mandayam, S.; Mitani, A.A.; Chang, T.I.; Ding, V.Y.; Brookhart, M.A.; Goldstein, B.A.; Winkelmayer, W.C. Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients. Nephrol. Dial. Transplant. 2015, 30, 2068–2073 doi:10.1093/ndt/gfv305.
136. Hazara, A.M.; Bhandari, S. Intravenous iron administration is associated with reduced platelet counts in patients with chronic kidney disease. J. Clin. Pharm. Ther. 2015, 40, 20–23. doi:10.1111/jcpt.12218.
137. Zitt, E.; Sturm, G.; Kronenberg, F.; Neyer, U.; Knoll, F.; Lhotta, K.; Weiss, G. Iron supplementation and mortality in incident dialysis patients: An observational study. PLoS ONE 2014, 9. doi:10.1371/journal.pone.0114144.
138. Schiller, B.; Bhat, P.; Sharma, A. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the united states over a 12-month period. Clin. Ther. 2014, 36, 70–83. doi:10.1016/j.clinthera.2013.09.028.
139. Ishida, J.H.; Marafino, B.J.; McCulloch, C.E.; Dalrymple, L.S.; Dudley, R.A.; Grimes, B.A.; Johansen, K.L. Receipt of intravenous iron and clinical outcomes among hemodialysis patients hospitalized for infection. Clin. J. Am. Soc. Nephrol. 2015, 10, 1799–1805. doi:10.2215/CJN.01090115.
140. Tangri, N.; Miskulin, D.C.; Zhou, J.; Bandeen-Roche, K.; Michels, W.M.; Ephraim, P.L.; McDermott, A.; Crews, D.C.; Scialla, J.J.; Sozio, S.M. et al. Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: A comparative effectiveness analysis from the decide-esrd study. Nephrol. Dial. Transplant. 2015, 30, 667–675. doi:10.1093/ndt/gfu349.
141. Miskulin, D.C.; Tangri, N.; Bandeen-Roche, K.; Zhou, J.; McDermott, A.; Meyer, K.B.; Ephraim, P.L.; Michels, W.M.; Jaar, B.G.; Crews, D.C. et al. Intravenous iron exposure and mortality in patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 2014, 9, 1930–1939. doi:10.2215/CJN.03370414.
142. Kshirsagar, A.V.; Freburger, J.K.; Ellis, A.R.; Wang, L.; Winkelmayer, W.C.; Brookhart, M.A. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS ONE 2013, 8. doi:10.1371/journal.pone.0078930.
143. Garcia-Lopez, S.; Bocos, J.M.; Gisbert, J.P.; Bajador, E.; Chaparro, M.; Castano, C.; Garcia-Erce, J.A.; Gomollon, F. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: Early efficacy and impact on quality of life. Blood Transfus. 2016, 14, 199–205. doi:10.2450/2016.0246-15.
144. Cortes, X.; Borras-Blasco, J.; Moles, J.R.; Bosca, M.; Cortes, E. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: A pilot study. PLoS ONE 2015, 10. doi:10.1371/journal.pone.0128156.
145. Befrits, R.; Wikman, O.; Blomquist, L.; Hjortswang, H.; Hammarlund, P.; Bajor, A.; Klintman, D.; Blom, H. Anemia and iron deficiency in inflammatory bowel disease: An open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life. Scand. J. Gastroenterol. 2013, 48, 1027–1042 doi:10.3109/00365521.2013.819442.
146. Froessler, B.; Collingwood, J.; Hodyl, N.A.; Dekker, G. Intravenous ferric carboxymaltose for anaemia in pregnancy. BMC Preg. Childbirth 2014, 14. doi:10.1186/1471-2393-14-115.
147. Calleja, J.L.; Delgado, S.; del Val, A.; Hervas, A.; Larraona, J.L.; Teran, A.; Cucala, M.; Mearin, F.; Colon Cancer Study, G. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Int. J. Colorectal Dis. 2016, 31, 543–551. doi:10.1007/s00384-015-2461-x.
148. Toledano, A.; Luporsi, E.; Morere, J.F.; Scotte, F.; Laribi, K.; Barriere, J.; Huot-Marchand, P.; Duvillie, L.; Concas, V.H.; Bugat, R. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. Support. Care Cancer 2016, 24, 67–75. doi:10.1007/s00520-015-2728-3.
149. KDIGO. Kidney disease: Improving global outcomes (kdigo) anemia work group. Kdigo clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2012, 2, 279–335.
150. Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.; Coats, A.J.; Falk, V.; Gonzalez-Juanatey, J.R.; Harjola, V.P.; Jankowska, E.A. et al. 2016 esc guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (esc). Developed with the special contribution of the heart failure association (hfa) of the esc. Eur. J. Heart Fail. 2016, 18, 891–975. doi:10.1002/ejhf.592.
151. Aapro, M.; Beguin, Y.; Bokemeyer, C.; Dicato, M.; Gascon, P.; Glaspy, J.; Hofmann, A.; Link, H.; Littlewood, T.; Ludwig, H. et al. Management of anaemia and iron deficiency in patients with cancer: Esmo clinical practice guidelines. Ann. Oncol. 2018, doi:10.1093/annonc/mdx758.
152. Mikhail, A.; Brown, C.; Williams, J.A.; Mathrani, V.; Shrivastava, R.; Evans, J.; Isaac, H.; Bhandari, S. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol. 2017, 18. doi:10.1186/s12882-017-0688-1.
153. Jankowska, E.A.; Rozentryt, P.; Witkowska, A.; Nowak, J.; Hartmann, O.; Ponikowska, B.; Borodulin-Nadzieja, L.; Banasiak, W.; Polonski, L.; Filippatos, G. et al. Iron deficiency: An ominous sign in patients with systolic chronic heart failure. Eur. Heart J. 2010, 31, 1872–1880. doi:10.1093/eurheartj/ehq158.
154. Klip, I.T.; Comin-Colet, J.; Voors, A.A.; Ponikowski, P.; Enjuanes, C.; Banasiak, W.; Lok, D.J.; Rosentryt, P.; Torrens, A.; Polonski, L. et al. Iron deficiency in chronic heart failure: An international pooled analysis. Am. Heart J. 2013, 165, 575–582. doi:10.1016/j.ahj.2013.01.017.
155. Klip, I.T.; Jankowska, E.A.; Enjuanes, C.; Voors, A.A.; Banasiak, W.; Bruguera, J.; Rozentryt, P.; Polonski, L.; van Veldhuisen, D.J.; Ponikowski, P. et al. The additive burden of iron deficiency in the cardiorenal-anaemia axis: Scope of a problem and its consequences. Eur. J. Heart Fail. 2014, 16, 655–662. doi:10.1002/ejhf.84.
156. Ponikowski, P.; Filippatos, G.; Colet, J.C.; Willenheimer, R.; Dickstein, K.; Luscher, T.; Gaudesius, G.; von Eisenhart Rothe, B.; Mori, C.; Greenlaw, N. et al. The impact of intravenous ferric carboxymaltose on renal function: An analysis of the fair-hf study. Eur. J. Heart Fail. 2015, 17, 329–339. doi:10.1002/ejhf.229.
157. Clinicaltrials.Gov. Intravenous Iron Treatment in Patients with Heart Failure and Iron Deficiency: Ironman. NCT02642562. Available online: https://clinicaltrials.gov/ct2/show/NCT02642562 (accessed on 07 June 2018).
158. Alves, R.A.; Miszputen, S.J.; Figueiredo, M.S. Anemia in inflammatory bowel disease: Prevalence, differential diagnosis and association with clinical and laboratory variables. Sao Paulo Med. J. 2014, 132, 140–146.
159. Filmann, N.; Rey, J.; Schneeweiss, S.; Ardizzone, S.; Bager, P.; Bergamaschi, G.; Koutroubakis, I.; Lindgren, S.; Morena Fde, L.; Moum, B. et al. Prevalence of anemia in inflammatory bowel diseases in european countries: A systematic review and individual patient data meta-analysis. Inflamm. Bowel Dis. 2014, 20, 936–945. doi:10.1097/01.MIB.0000442728.74340.fd.
160. Kaitha, S.; Bashir, M.; Ali, T. Iron deficiency anemia in inflammatory bowel disease. World J. Gastrointest. Pathophysiol. 2015, 6, 62–72. doi:10.4291/wjgp.v6.i3.62.
161. Aksan, A.; Isik, H.; Radeke, H.H.; Dignass, A.; Stein, J. Systematic review with network meta-analysis: Comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2017, 45, 1303–1312 doi:10.1111/apt.14043.
162. Schaefer, B.; Wurtinger, P.; Finkenstedt, A.; Braithwaite, V.; Viveiros, A.; Effenberger, M.; Sulzbacher, I.; Moschen, A.; Griesmacher, A.; Tilg, H. et al. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS ONE 2016, 11. doi:10.1371/journal.pone.0167146.
163. Adkinson, N.F.; Strauss, W.E.; Macdougall, I.C.; Bernard, K.E.; Auerbach, M.; Kaper, R.F.; Chertow, G.M.; Krop, J.S. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. Am. J. Hematol. 2018, 93, 683–690. doi:10.1002/ajh.25060.
164. Bager, P.; Hvas, C.L.; Dahlerup, J.F. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br. J. Clin. Pharmacol. 2017, 83, 1118–1125. doi:10.1111/bcp.13189.
165. Wang, C.; Graham, D.J.; Kane, R.C.; Xie, D.; Wernecke, M.; Levenson, M.; MaCurdy, T.E.; Houstoun, M.; Ryan, Q.; Wong, S. et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015, 314, 2062–2068. doi:10.1001/jama.2015.15572.
166. Kalra, P.A.; Bhandari, S. Safety of intravenous iron use in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2016, 25, 529–535. doi:10.1097/MNH.0000000000000263.
167. Camaschella, C. Iron-deficiency anemia. N. Engl. J. Med. 2015, 372, 1832–1843. doi:10.1056/NEJMra1401038.